Effect of alteplase versus aspirin plus clopidogrel in acute minor stroke
- 12 January 2020
- journal article
- research article
- Published by Taylor & Francis in International Journal of Neuroscience
- Vol. 130 (9) , 857-864
Abstract
Background and purpose: The optimal treatment for acute ischemic stroke with mild neurologic deficits is unclear. We aimed to compare the efficacy and safety of alteplase versus dual-antiplatelet therapy in acute minor stroke. Methods: We performed a retrospective cohort study of patients with minor ischemic stroke and National Institutes of Health Stroke Scale scores ≤5 presenting within 24 h from last seen normal. Patients were divided into intravenous alteplase or dual-antiplatelet therapy group. The primary outcome was a modified Rankin Scale (mRS) score of 0 or 1 at 90 days. Secondary outcomes included mRS score at 7 days, and composite outcome of vascular events within 90 days. The safety outcome was any intracranial hemorrhage (ICH) according to the ECASS II criteria. Clinical outcomes were compared using a multivariable logistic regression after adjusting for confounding factors. We then performed the propensity score matching as a sensitivity analysis. Results: Two hundred twenty-eight patients met the eligibility criteria were included for analysis between January 2015 and September 2018. In the aspirin-clopidogrel group, 109 patients (91.6%) achieved a favorable functional outcome at 3-month versus 85(78.0%) in the alteplase group (OR 4.463, 95%CI 1.708–11.662, p = .002). The difference of the composite outcome of vascular events were not statistical significance between the two groups (p > .05). Asymptomatic ICH occurred in 0.8% patients who received aspirin-clopidogrel, as compared with 3.7% patients in alteplase group (p = .030). Conclusions: Patients treated with dual-antiplatelet therapy with acute minor ischemic stroke had greater functional outcome at 3 months compared with patients who received alteplase therapy. Classification of evidence: This study provides Class IV evidence that dual-antiplatelet therapy is superior to alteplase for achieving a better functional outcome and does not increase the risk of hemorrhage in acute minor ischemic stroke.Keywords
This publication has 19 references indexed in Scilit:
- Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIANew England Journal of Medicine, 2018
- Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic DeficitsJAMA, 2018
- 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke AssociationStroke, 2018
- One-year outcomes and secondary prevention in patients after acute minor stroke: results from the China National Stroke RegistryNeurological Research, 2017
- Thrombolysis for Acute Minor Stroke: Outcome and Barriers to ManagementCerebrovascular Diseases, 2015
- Outcomes in Mild Acute Ischemic Stroke Treated With Intravenous ThrombolysisJAMA Neurology, 2015
- Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic AttackNew England Journal of Medicine, 2013
- Implementation and outcome of thrombolysis with alteplase 3–4·5 h after an acute stroke: an updated analysis from SITS-ISTRThe Lancet Neurology, 2010
- What Is a Minor Stroke?Stroke, 2010
- Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trialThe Lancet Neurology, 2008